Previous Close | 14.06 |
Open | 13.95 |
Bid | 14.01 x 4000 |
Ask | 0.00 x 3000 |
Day's Range | 13.86 - 14.10 |
52 Week Range | 7.09 - 14.47 |
Volume | |
Avg. Volume | 9,288,291 |
Market Cap | 15.8B |
Beta (5Y Monthly) | 1.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.50 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | 15.50 |
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, May 08, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the
Shares of Teva Pharmaceutical Industries have done something unusual this year: They’ve gone up. The company’s American depositary receipt, which spent much of the past decade falling in value or stagnating at rock-bottom levels, has shot up nearly 35% this year. On Wednesday morning, executives will present the Teva’s first-quarter results, and face questions from Wall Street about whether the company can sustain this upswing.
In this article, we will be taking a look at the 20 states with the highest fertility rates in the US. If you do not want to learn about the US fertility services market, head straight to the 5 States with the Highest Fertility Rates in the US. Expanding Horizons: The Global and US Fertility […]